Tia L Bush
CIK 1863418 · Chief Technology & Quality Ofc · last filed 2026-06-24
Tia L Bush is a Chief Technology & Quality Ofc who has filed 36 SEC Form 4 insider transactions across 1 company since 2021. The most recent filing, for CNTA, was dated Jun 24, 2026. Across all open-market trades the lifetime net is −$4.6M, making them a net seller over the disclosed history. 9 Form 144 notices of planned sales are also on file; the latest, for Centessa Pharmaceuticals plc on Nov 17, 2025, lists the filer as an officer. 6 sales listed on those notices, worth $3.4M in all, have no matching Form 4.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CNTA price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM
CHESHIRE, X0 WA14 2DT
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Centessa Pharmaceuticals plc (CNTA) Delisted | Chief Technology & Quality Ofc | 0 | $40.50 | $0 | -$4.64M | 27 | 2026-06-24 |
Holdings By Holder
| Symbol | Holder | Shares | Share of Total | Reported |
|---|---|---|---|---|
| CNTA | Direct | 0 | — | 2026-06-24 |
| By spouse | 0 | — | 2023-05-26 | |
| Total | 0 |
Recent Filings
36 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-24 | Centessa Pharmaceuticals plc (CNTA) Delisted | Disp (D) | −147,954 | $0 | EDGAR |
| 2026-02-03 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed | +26,451 | -$210.0K | EDGAR |
| 2025-11-18 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed10b5-1 Plan adopted Sep 14, 2024 |
— | -$743.2K | EDGAR |
| 2025-11-17 | Centessa Pharmaceuticals plc | Notice (144) Officer · Planned Nov 17, 2025 · 10b5-1 plan No sale on file |
−40,000 | -$1.12M | EDGAR |
| 2025-11-13 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed10b5-1 Plan adopted Sep 14, 2024 |
— | -$663.2K | EDGAR |
| 2025-11-12 | Centessa Pharmaceuticals plc | Notice (144) Officer · Planned Nov 12, 2025 · 10b5-1 plan Sold: listed on the Nov 17, 2025 notice |
−40,000 | -$1.04M | EDGAR |
| 2025-09-24 | Centessa Pharmaceuticals plc | Notice (144) Officer · Planned Sep 24, 2025 · 10b5-1 plan Sold: listed on the Nov 12, 2025 notice |
−35,000 | -$840.0K | EDGAR |
| 2025-09-24 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed10b5-1 Plan adopted Sep 14, 2024 |
— | -$510.3K | EDGAR |
| 2025-09-11 | Centessa Pharmaceuticals plc (CNTA) Delisted | Mixed10b5-1 Plan adopted Sep 14, 2024 |
— | -$611.8K | EDGAR |
| 2025-09-10 | Centessa Pharmaceuticals plc | Notice (144) Officer · Planned Sep 10, 2025 · 10b5-1 plan Sold: listed on the Sep 24, 2025 notice |
−25,000 | -$550.0K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).
Sales Reported Only on Form 144
6 sales · $3.40M| Sold | Symbol | Shares | Proceeds | Avg Price | Listed On |
|---|---|---|---|---|---|
| 2025-11-12 | Centessa Pharmaceuticals plc | 40,000 | $1.04M | $26.00 | 2025-11-17 |
| 2025-09-24 | Centessa Pharmaceuticals plc | 35,000 | $840.0K | $24.00 | 2025-11-12 |
| 2025-09-10 | Centessa Pharmaceuticals plc | 25,000 | $550.0K | $22.00 | 2025-09-24 |
| 2025-09-09 | Centessa Pharmaceuticals plc | 24,792 | $495.8K | $20.00 | 2025-09-10 |
| 2024-12-17 | Centessa Pharmaceuticals plc | 17,813 | $320.6K | $18.00 | 2025-02-03 |
| 2024-12-16 | Centessa Pharmaceuticals plc | 9,611 | $157.3K | $16.36 | 2024-12-17 |